<Page>
Exhibit 10.12
SYNTA PHARMACEUTICALS CORP. HAS REQUESTED THAT THE MARKED PORTIONS
OF THIS
DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 406
UNDER THE
SECURITIES ACT OF 1933, AS AMENDED.
[*] DENOTES WHERE CONFIDENTIAL MATERIALS HAVE BEEN OMITTED AND
FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
ASSET PURCHASE AGREEMENT
Asset Purchase Agreement dated as of December 17, 2003, by and
among SYNTA
PHARMACEUTICALS CORP., a Delaware corporation ("Buyer"), CANCER
GENOMICS, INC.,
a Delaware corporation ("CG"), KAVA PHARMACEUTICALS, INC., a
Delaware
corporation ("Kava"), SINGLEPIXEL BIOMEDICAL, INC., a Delaware
corporation
("SinglePixel"; CG, Kava and SinglePixel shall singly and
collectively be
referred to herein as a "Seller" or "Sellers") and CMAC, LLC, a
Delaware limited
liability company ("Stockholder").
This
Agreement sets forth the terms and conditions upon which the
Buyer
will purchase from the Sellers, and Sellers (each severally and not
jointly)
will sell to the Buyer, all the assets of such Sellers (other than
the Retained
Assets, as hereinafter defined) and the business and goodwill of
the Sellers as
a going concern, subject to those liabilities of the Sellers which
are
specifically hereinafter described, for the consideration provided
herein.
In
all instances, except where otherwise provided, each Seller's
rights and
obligations hereunder shall be deemed several and not joint among
the Sellers.
In
consideration of the foregoing, the mutual representations,
warranties
and covenants set forth herein, and for other good and valuable
consideration,
the receipt and sufficiency of which are hereby acknowledged, the
parties to
this Agreement hereby agree as follows:
ARTICLE I
DEFINITIONS
1.1
DEFINITIONS. For the
purposes of this Agreement, all capitalized words
or expressions used in this Agreement shall have the meanings
specified in this
Article I (such meanings to be equally applicable to both the
singular and
plural forms of the terms defined):
"AFFILIATE" means when used with respect to any Person, if such
Person is a
corporation, any officer or director thereof and any Person which
is, directly
or indirectly, the beneficial owner (by itself or as part of any
group) of more
than fifty percent (50%) of any class of any Equity Security
thereof, and, if
such beneficial owner is a partnership, any general or limited
partner thereof,
or if such beneficial owner is a corporation, any Person
controlling, controlled
by or under common control with such beneficial owner, or any
officer or
director of such beneficial owner or of any corporation occupying
any such
control relationship.
"AGREEMENT" means this Asset Purchase Agreement (together with all
Exhibits
and Schedules hereto) as in effect from time to time.
"BUSINESS DAY" means any day, excluding Saturday, Sunday and any
other day
on which commercial banks in Boston, Massachusetts are authorized
or required by
law to close.
1
<Page>
"CHARTER" means the Certificate of Incorporation, Articles of
Incorporation
or Organization or other organizational document of a corporation,
as amended
and restated through the date hereof.
"CLAIM" means an action, suit, proceeding, hearing,
investigation,
litigation, charge, complaint, claim or demand.
"CODE" means the Internal Revenue Code of 1986, and the
regulations,
rulings, and court decisions in respect thereof, all as the same
shall be in
effect at the time.
"COMMISSION" means the Securities and Exchange Commission and any
other
similar or successor agency of the federal government administering
the
Securities Act or the Exchange Act.
"ENVIRONMENTAL ACTION" means any administrative, regulatory or
judicial
action, suit, demand, claim, notice of non-compliance or
violation,
investigation, request for information, proceeding, consent order
or consent
agreement relating in any way to any Environmental Law or any
Environmental
Permit.
"ENVIRONMENTAL LAW" means any applicable federal, state or local
law,
statute, rule, regulation, or ordinance relating to the
environment, human
health or safety from pollution or other environmental degradation
or Hazardous
Materials.
"EQUITY SECURITY" shall have the meaning given to such term in
Section
3(a)(ii) of the Exchange Act.
"ERISA" means the Employee Retirement Income Security Act of 1974,
and any
similar or successor federal statute, and the rules, regulations
and
interpretations thereunder, all as the same shall be in effect at
the time.
"EXCHANGE ACT" means the Securities Exchange Act of 1934, and the
rules and
regulations and interpretations of the Commission thereunder, all
as the same
shall be in effect at the time.
"GAAP" means generally accepted accounting principles,
consistently
applied.
"LIEN" means, with respect to any asset, any mortgage, deed of
trust,
pledge, hypothecation, assignment, security interest, lien, charge,
restriction,
adverse claim by a third party, title defect or encumbrance of any
kind.
"MATERIAL ADVERSE EFFECT" means a material adverse impact or effect
on the
assets of a Seller or of the Buyer, as the case may be.
"OFFICER'S CERTIFICATE" means a certificate signed in the name of
a
corporation by its President, Chief Executive Officer, Treasurer,
Chief
Financial Officer, or, if so specified, the Secretary, acting in
his or her
official capacity.
2
<Page>
"PERSON" means any individual, firm, partnership, association,
trust,
corporation, limited liability company, governmental body or other
entity.
"PURCHASE DOCUMENTS" means this Agreement, the Non-Competition
Agreements,
the Bills of Sale, the Instruments of Assumption, the Patent
Assignments, the
Kava Pharmaceutical License Agreement and any other certificate,
document,
instrument, stock power, or agreement executed in connection
therewith.
"SECURITIES ACT" means the Securities Act of 1933 and the
rules,
regulations and interpretations of the Commission thereunder, all
as the same
shall be in effect at the time.
"SUBSIDIARY" means, with respect to any Person, any
corporation,
association or other entity of which such Person owns at least a
majority in
interest of the outstanding capital stock or other Equity
Securities having by
the terms thereof voting power under ordinary circumstances to
elect a majority
of the directors, managers or trustees thereof.
"TAX" means any federal, state, local or foreign tax of any
kind
whatsoever, including any interest, penalty, or addition thereto,
whether
disputed or not.
"TAX
RETURN" means any return, declaration, report, claim for refund,
or
information return or statement relating to Taxes, including any
schedule or
attachment thereto, and including any amendment thereof.
"TO
STOCKHOLDER'S KNOWLEDGE", "KNOWN TO STOCKHOLDER", "TO THE KNOWLEDGE
OF
THE STOCKHOLDER" and words of similar import means the actual
knowledge of any
of Michael R.L. Astor, Joel W. McCleary, Nicholas N. Noon and Todd
A. Klibansky
as of the date hereof.
"VALID CLAIM" shall mean a claim in an issued, unexpired patent or
in a
pending patent application within the Kava Patents, Single Pixel
Patents or CG
Patents that (a) has not been finally cancelled, withdrawn,
abandoned or
rejected by any administrative agency or other body of competent
jurisdiction,
(b) has not been revoked, held invalid, or declared unpatentable
or
unenforceable in a decision of a court or other body of competent
jurisdiction
that is unappealable or uappealed within the time allowed for
appeal, (c) has
not been rendered unenforceable through disclaimer or otherwise,
(d) is not lost
through an interference proceeding or (e) to the extent pending,
has not been
pending for longer than five (5) years from the filing date of the
earliest
patent application from which the pending application claims
priority, provided
that subsequent to such five (5) year period, if the pending claim
is issued as
a claim of an issued and unexpired patent within the Kava Patents,
Single Pixel
Patents or CG Patents, such claim shall be considered thereafter as
a Valid
Claim hereunder.
3
<Page>
The
following terms are defined in the following Sections of this
Agreement:
<Table>
<Caption>
Term
Section
----
-------
<S>
<C>
Agreement
Recitals
Assumed
Liabilities
2.1
Bills of Sale
2.8
Business
2.1
Buyer
Recitals
Closing
2.7
Closing Date
2.7
Seller Financial
Statements
3.4
Gross Revenues
2.5(b)
Indemnifying
Party
8.5
Instruments of
Assumption
2.9
Losses
8.2
Necessary
Permits
3.13
Non-Competition
Agreements
6.1
Patent
Assignment
6.1
Plan
3.15(a)
Purchased Assets
2.1
Purchase Price
2.2
Retained Assets
2.2
Retained
Liabilities
2.4
Stockholder
Recitals
</Table>
ARTICLE II
PURCHASE AND SALE OF ASSETS
2.1
PURCHASE OF ASSETS.
Upon the terms and subject to the conditions
contained in this Agreement, at the Closing (as defined in Section
2.7 below),
each Seller shall sell, assign, transfer and convey to Buyer, and
Buyer shall
purchase, acquire and accept from each Seller, the business of the
respective
Sellers as a going concern (the "Business"), including all of the
Sellers'
assets of every kind and description as set forth on SCHEDULE 2.1
hereto (the
"Purchased Assets") (other than those assets included in the
Retained Assets as
defined in Section 2.2 below), and subject only to the liabilities
and
obligations of the Sellers which are defined in Section 2.3 (the
"Assumed
Liabilities"). The Purchased Assets include, without limitation,
all assets,
rights, interests and properties of the Sellers (other than those
assets
included in the Retained Assets as defined in Section 2.2).
2.2
RETAINED ASSETS. The
Sellers will each retain ownership only of such
Seller's cash and cash equivalents on hand and in banks, minute and
stock record
books, journals, ledgers and books of original entry and such
Seller's rights
under the Purchase Documents (collectively, the "Retained
Assets").
4
<Page>
2.3
ASSUMED LIABILITIES.
The Buyer shall assume and agree to pay, perform
and discharge the Assumed Liabilities, and will pay, perform and
discharge the
Assumed Liabilities as they become due. The Assumed Liabilities
shall consist of
the liabilities of the Sellers listed on SCHEDULE 2.3 attached
hereto.
2.4
RETAINED LIABILITIES.
The liabilities and obligations which shall be
retained by each of the Sellers (the "Retained Liabilities") shall
consist of
all liabilities of such Seller other than Assumed Liabilities,
including,
without limitation, the following:
(a) all liabilities of
each Seller relating to indebtedness for
borrowed money whether or not such liabilities are reflected on the
Seller
Financial Statements;
(b) all liabilities of
each Seller or the Stockholder resulting from,
constituting or relating to a breach of any of the representations,
warranties,
covenants or agreements of the such Seller or the Stockholder under
this
Agreement;
(c) all liabilities of
each Seller for Taxes, including any gain and
income from the sale of the Assets and other transactions
contemplated herein;
(d)
all liabilities for
all environmental, ecological, health,
safety, products liability (except as specifically referred to
herein) or other
claims pertaining to the Business or the Purchased Assets which
relate to time
periods or events occurring on or prior to the Closing Date;
(e) all liabilities of
each Seller arising in connection with its
operations unrelated to the Business and all liabilities (including
any
liability pursuant to any claim, litigation or proceeding) in
connection with
the operation of the Business prior to the Closing except as
otherwise
specifically provided herein and any liability of such Seller based
on its
tortuous or illegal conduct;
(f) any liability or
obligation incurred by each Seller in connection
with the negotiation, execution or performance of this Agreement,
including,
without limitation, all legal, accounting, brokers', finders' and
other
professional fees and expenses;
(g) all liabilities
incurred by each Seller after the Closing Date;
(h) all liabilities or
obligations associated with a Seller's
employees, including but not limited to any liability or obligation
under or
with respect to any collective bargaining agreement, employment
agreement,
unemployment or workers' compensation laws, or any liability or
obligation
arising from the decision of Buyer not to offer employment to any
such
employees; and
(i) all liabilities
and obligations arising out of, resulting from,
or relating to any employee benefit plan, program, or arrangement
maintained or
contributed to by each Seller,
5
<Page>
or any entity which is or has been aggregated with such Seller for
purposes of
section 414 of the Code or section 4001 of ERISA.
2.5
PURCHASE PRICE. Upon
the terms and subject to the conditions contained
in this Agreement, and in consideration of the sale, assignment,
transfer and
delivery of the Purchased Assets and covenants not to compete
received from the
Sellers and the Stockholder, Buyer will issue to the Sellers an
aggregate of
553,344 shares of the Buyer's common stock, par value $0.0001 per
share ("Common
Stock" and the "Consideration Shares", and together with the
adjustments set
forth below, the "Purchase Price"). The Consideration Shares shall
be
apportioned among the Sellers as follows: 25% to CG, 50% to Kava
and 25% to
SinglePixel. Delivery of stock certificates representing the
Consideration
Shares shall be made to each of the Sellers at the Closing. The
parties agree
that the Purchase Price represents fair consideration and
reasonably equivalent
value for the Purchased Assets.
(a) ADJUSTMENTS FOR
MILESTONES. Buyer shall make a one-time only
payment:
(i) to Kava, or any of
its assignees, of [*] payable in either
cash
or shares of the Buyer's Common Stock (at the discretion of the
Buyer
and,
if such payment is in Common Stock, valued at the then current
fair
market value of the Common Stock) in a single payment by wire
transfer or
delivery of shares of Common Stock to an account designated in
writing by
Kava, or any of its assignees, to Buyer within sixty (60) days of
the
commencement by Buyer of a Phase III (or other pivotal) clinical
trial for
any
drug candidate, the manufacture, use or sale of which infringes one
or
more
Valid Claims of the Kava Patents (a "Kava Drug Candidate"). For
purposes of this Agreement, "Kava Patents" shall mean any and all
patent
filings assigned to Kava or to which Kava has or will have any
right,
title or interest, including the issued patents and pending
patent
applications under the Kava IP (as defined in SCHEDULE 2.1), and
all
non-provisionals, divisionals, continuations, continuations-in-part
and
all
patents issuing on any of the foregoing, and all foreign
counterparts
thereof; together with all registrations, reissues,
re-examinations,
supplemental protection certificates and extensions thereof and
all
foreign counterparts thereof. In the event that Buyer commences a
Phase
III
(or other pivotal) clinical trial for a drug candidate, the
manufacture, use of sale of which does not infringe one or more
Valid
Claims of the Kava Patents at the time of the commencement of
such
clinical trial but the manufacture, use or sale of which later
infringes
one
or more Valid Claims of the Kava Patents, then Buyer shall make
such
one-time only payment under this subsection (i) of Section 2.5(a)
within
sixty (60) days of the drug candidate becoming a Kava Drug
Candidate under
this
Agreement; and
(ii) to SinglePixel, or any of its assignees, [*] payable in
either cash or shares of the Buyer's Common Stock (at the
discretion of
the
Buyer and, if such payment is in Common Stock, valued at the
then
current fair market value of the Common Stock) in a single payment
by wire
transfer or delivery of shares of Common Stock to an account
designated in
writing by SinglePixel, or any of its assignees, to Buyer within
sixty
(60)
days of the receipt by Buyer of approval by the Federal Drug
Administration of any SinglePixel diagnostic product, the
6
<Page>
manufacture, use or sale of which infringes one or more Valid
Claims of the
SinglePixel Patents (a "SinglePixel Product"). For purposes of
this
Agreement, "SinglePixel Patents" shall mean any and all patent
filings
assigned to SinglePixel or to which SinglePixel has or will have
any right,
title or interest, including the issued patents and pending
patent
applications identified under the SinglePixel IP (as defined in
SCHEDULE
2.1), and all non-provisionals, divisionals, continuations,
continuations-in-part and all patents issuing on any of the
foregoing, and
all
foreign counterparts thereof; together with all registrations,
reissues, re-examinations, supplemental protection certificates
and
extensions thereof. In the event that Buyer receives approval by
the
Federal Drug Administration of any SinglePixel diagnostic product,
the
manufacture, use or sale of which does not infringes one or more
Valid
Claims of the SinglePixel Patents at the time of receipt of such
approval
but
the manufacture, use or sale of which later infringes one or more
Valid
Claims of the SinglePixel Patents, then Buyer shall make such
one-time only
payment under this subsection (ii) of Section 2.5(a) within sixty
(60) days
of
the SinglePixel diagnostic product becoming a SinglePixel Product
under
this
Agreement. For purposes of this Section 2.5, the term
"diagnostic
product" means any product which is intended to predict, detect or
identify
a
disease, determine the presence of a pathologic condition or
monitor the
course of disease or therapy in humans or other animals.
(b) ROYALTIES FOR
CERTAIN PATENTS. In the event that Buyer
obtains revenue or other measurable economic benefit ("Gross
Revenues") from
products or services covered by a Valid Claim in any Kava Patent or
CG Patent
(the "Kava Products", and the "CG Products", respectively), Buyer
shall pay
to Kava or CG, or any of their assignees, as the case may be, a
percentage of
the Gross Revenues received by Buyer or such licensee from sales of
such Kava
Product or CG Product as follows: (i) [*]% of Gross Revenues of the
Kava
Product, and (ii) [*]% of Gross Revenues of the CG Product. The
amount of
such Gross Revenues shall be proportionately adjusted to reflect
the
exclusion of the contribution of ingredients or components not
directly
related to the Kava Product and/or CG Product, but in no case less
than [*]%
of the rates specified above. Any payments by Buyer pursuant to
this
subsection shall be made by cash or check within ninety (90) days
of the end
of each fiscal year of Buyer in which any applicable sale is made.
The
obligations under this section shall continue on a
country-by-country basis
until the later of (1) the expiration date, as such date may be
modified or
extended, of the last-to-expire patent of the relevant Kava IP or
CG IP (as
the case may be) in such country, or (2) ten (10) years from first
commercial
sale of the Kava Product or CG Product. For purposes of this
Section 2.5, "CG
Patents" shall mean any and all patent filings assigned to CG or to
which CG
has or will have any right, title or interest, including the issued
patents
and pending patent applications identified under the CG IP (as
defined in
SCHEDULE 2.1), and all non-provisionals, divisionals,
continuations,
continuations-in-part; and all patents issuing on any of the
foregoing, and
all foreign counterparts thereof; together with all registrations,
reissues,
re-examinations, supplemental protection certificates and
extensions thereof.
(c) THIRD PARTY
ROYALTY OFFSET. In the event that in any royalty
period, Buyer, in order to sell any Kava Product or CG Product in
any country,
makes royalty payments to one or more third parties ("Third Party
Payments") as
consideration for a license to an issued patent or patents owned by
such third
party(ies), in the absence of which the Kava Product or CG Product
could not
legally be made, used or sold in such country, then Buyer shall
have the right
7
<Page>
to reduce the royalties otherwise due pursuant to Section 2.5(b)
above for
such Kava Product or CG Product by [*]% of such Third Party
Payments.
Notwithstanding the foregoing, such reductions under this
subsection (c)
shall in no event reduce such royalty for such Kava Product or CG
Product in
any such country to less than [*]% of the rates otherwise specified
above.
2.6
ALLOCATION OF PURCHASE
PRICE. The Purchase Price shall be allocated
among the Purchased Assets and the covenants not to compete
received from the
Sellers and the Stockholder as set forth in SCHEDULE 2.6 attached
hereto. The
Sellers and Buyer shall be bound by such allocation for all
purposes and to
account for and report the purchase and sale contemplated hereby
for all
financial, accounting and Tax purposes in accordance with such
allocation.
2.7
TIME AND PLACE OF
CLOSING. The closing of the transactions described
in Sections 2.1 through 2.6 above (the "Closing") shall take place
at the
offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., at
11:00 a.m. on
January 9, 2004, or at such other place or time as the parties
hereto may agree.
The date and time at which the Closing actually occurs is
hereinafter referred
to as the "Closing Date."
2.8
EXECUTION AND DELIVERY
OF DOCUMENTS OF TITLE BY THE SELLERS. At the
Closing, each Seller shall execute and deliver to Buyer the form of
Bill of Sale
attached hereto as EXHIBIT A and such deeds, conveyances, bills of
sale,
certificates of title, assignments, assurances and other
instruments and
documents as Buyer may reasonably request in order to effect the
sale,
conveyance, and transfer of the Purchased Assets from the Sellers
to the Buyer.
Such instruments and documents shall be sufficient to convey to
Buyer good and
merchantable title in all of the Purchased Assets. Each Seller
will, from time
to time after the Closing Date, take such additional actions and
execute and
deliver such further documents as Buyer may reasonably request in
order more
effectively to sell, transfer and convey the Purchased Assets to
Buyer and to
place Buyer in position to operate and control all of the Purchased
Assets.
2.9
EXECUTION AND DELIVERY
OF DOCUMENTS BY BUYER. At the Closing, Buyer
shall execute and deliver to each Seller an Instrument of
Assumption in the form
attached hereto as EXHIBIT B, and such other documents as the
Sellers may
reasonably request in order to evidence Buyer's assumption of the
Assumed
Liabilities. Buyer will, from time to time after the Closing Date,
take such
additional action and deliver such further documents as the Sellers
may
reasonably request in order effectively to assume the Assumed
Liabilities.
2.10
CONSENT TO ASSIGNMENT. Upon the terms, and subject to the
conditions
set forth in this Agreement, each Seller hereby assigns to the
Buyer all of the
Purchased Assets which are capable of assignment without the
consent of other
parties.
Insofar as any Purchased Asset is not assignable to the Buyer
without the
agreement of or novation by or consent to the assignment from
another party and
no such agreement, novation or consent has been obtained by such
Seller on or
prior to Closing Date, this Agreement shall not constitute an
assignment or
attempted assignment if such assignment or attempted assignment
would constitute
a breach of Seller's obligations related to such Purchased Asset.
In the event
that consent or novation is required to such assignment:
8
<Page>
(a) the Seller shall
use all reasonable endeavors to cooperate with
the Buyer in its efforts to procure such novation or assignment as
aforesaid.
The reasonable costs of any such novation or assignment shall be
paid by the
Buyer;
(b) unless and until
any such Purchased Asset shall be novated or
assigned as aforesaid the Seller shall hold such Purchased Asset
and any moneys,
goods or other benefits received thereunder as agent of the Buyer
and the Buyer
shall (if such sub-contracting is permissible and lawful under such
Purchased
Asset in question) as the Seller's sub-contractor perform all the
obligations of
the Seller under such Purchased Asset;
(c) unless and until
any such Purchased Asset shall be novated or
assigned, the Seller will (so far as it lawfully may) give such
assistance to
the Buyer (and at the Buyer's cost) as the Buyer may reasonably
require to
enable the Buyer to enforce its rights under such Purchased Asset
and (without
limitation) will provide access to all relevant books, documents
and other
information in relation to such Purchased Asset as the Buyer may
reasonably
require from time to time.
ARTICLE III
REPRESENTATIONS AND WARRANTIES
OF THE SELLERS AND THE STOCKHOLDER
Each
Seller and the Stockholder each hereby represents and warrants
to
Buyer as follows:
3.1
ORGANIZATION AND
QUALIFICATION. Each Seller is a corporation duly
organized, validly existing and in good standing under the laws of
the State of
Delaware. The Stockholder is a limited liability company duly
organized, validly
existing and in good standing under the laws of the State of
Delaware. The
Stockholder and each Seller have full power and authority to own,
use and lease
their properties and to conduct their business as currently
conducted and as
proposed to be conducted. The copies of the Stockholder's operating
agreement,
as amended to date and certified by an officer of the Stockholder
and delivered
to Buyer's counsel prior to the Closing, is true, complete and
correct. The
copies of each Seller's Charter and By-Laws, as amended to date, in
each case
certified by their respective Secretaries and delivered to Buyer's
counsel prior
to the Closing, are true, complete and correct.
3.2
AUTHORITY; NO
VIOLATION. Each Seller and the Stockholder has all
requisite corporate power and authority to enter into this
Agreement and to
carry out the transactions contemplated hereby. The execution,
delivery and
performance of this Agreement by each Seller and the Stockholder
have been duly
and validly authorized and approved by all necessary corporate
action. This
Agreement constitutes the legal and binding obligation of each
Seller and the
Stockholder, enforceable against each of them in accordance with
its terms. The
entering into of this Agreement by the Stockholder and each Seller
does not, and
the consummation by such Seller and the Stockholder of the
transactions
contemplated hereby, including specifically the transfer of the
Purchased Assets
to Buyer by such Seller, will not violate the provisions of (a) to
the knowledge
of the Stockholder, any applicable federal, state, local or foreign
laws, (b)
such
9
<Page>
Seller's or Stockholder's respective Charter, By-Laws or operating
agreement, as
the case may be, or (c) any provision of, or result in a default or
acceleration
of any obligation under, or result in any change in the rights or
obligations of
such Seller or the Stockholder under, any Lien, contract,
agreement, license,
lease, instrument, indenture, order, arbitration award, judgment,
or decree to
which such Seller or the Stockholder is a party or by which any of
them is
bound, or to which any property of such Seller or the Stockholder
is subject.
3.3
SUBSIDIARIES. Each
Seller represents and warrants that it has no
Subsidiaries.
3.4
SELLER FINANCIAL
STATEMENTS. Attached hereto as SCHEDULE 3.4 are
unaudited consolidating balance sheets as of June 30, 2003
(collectively, the
"Seller Financial Statements") for each Seller. The Seller
Financial Statements
have been prepared in accordance with GAAP applied on a consistent
basis
throughout the periods covered thereby. The Stockholder represents
and warrants
that the Seller Financial Statements fairly present the financial
condition and
the results of operation of each Seller and that there are no
assets of the
Sellers that are not included in the Seller Financial Statements,
except for
assets of any Seller that are not required by GAAP to be included
in the Seller
Financial Statements.
3.5
ABSENCE OF CERTAIN
CHANGES. Except as otherwise disclosed in SCHEDULE
3.5 attached hereto, since June 30, 2003, there has not been:
(a) any material
change in the business, operations, assets,
liabilities, prospects or condition (financial or otherwise) of any
Seller;
(b) any obligation or
liability incurred by a Seller other than
obligations and liabilities incurred in the ordinary course of
business for an
amount not more than $5,000 in each case or $15,000 in the
aggregate;
(c) any Lien placed on
any of the Sellers' properties or assets which
remains in existence on the date hereof or any payment or discharge
of a
material Lien or liability of the Sellers not disclosed on the
Seller Financial
Statements or incurred in the ordinary course of business;
(d) any purchase,
sale, lease, assignment, transfer or other
disposition, or any agreement or other arrangement for the
purchase, sale,
lease, assignment, transfer or other disposition, of any part of
the Sellers'
properties or assets, other than purchases for and sales from
inventory in the
ordinary course of business, except for fixed assets purchased or
other capital
expenditures made in amounts not exceeding $5,000 for any single
item and
$25,000 in the aggregate for all such items;
(e) any damage,
destruction or loss, whether or not covered by
insurance, adversely affecting a Seller's properties, assets or
business;
(f) any declaration,
setting aside or payment of any dividend on, or
the making of any other distribution in respect of, any Equity
Security of a
Seller, or any direct or
10
<Page>
indirect redemption, purchase or other acquisition by a Seller of
any of its own
Equity Securities, or any issuance by a Seller of any Equity
Security;
(g) any labor trouble
or claim of unfair labor practices involving a
Seller; any change in the employment contracts of or compensation
payable or to
become payable by a Seller to any of its current or former
officers, directors,
employees, consultants, or agents, or any bonus payment, loan or
arrangement
made to or with respect to any of such officers, directors,
employees,
consultants, or agents; or any change in coverage vesting, or
benefits available
under any Plan;
(h) any change with
respect to a Seller's management or supervisory
personnel;
(i) any contracts,
licenses, leases or agreements entered into by a
Seller which are outside the ordinary course of business or which
obligate such
Seller for more than $5,000 in any one case or more than $25,000 in
the
aggregate or any cancellation, termination, modification, or
acceleration by any
party to any contract, license, lease or agreement involving more
than $10,000
to which any such Seller is a party or by which any of them is
bound;
(j) any amendment or
other change (or any authorization to make such
an amendment or change) to such Seller's Charter or By-Laws, except
as required
in connection with the consummation of the transactions
contemplated hereby;
(k) any postponement
or delay in payment of any accounts payable or
other liability of such Seller except in the ordinary course of
business
consistent with prior practices;
(l) any cancellation,
waiver, compromise or release of any right or
claim either involving more than $10,000 or outside the ordinary
course of
business consistent with prior practices;
(m) any other
occurrence, action, failure to act or transaction
involving a Seller other than transactions in the ordinary course
of business
consistent with prior practices.
3.6
TITLE, SUFFICIENCY AND
CONDITION OF ASSETS. Except as disclosed in
SCHEDULE 3.6 hereto, each Seller has good and marketable title to,
or a valid
leasehold interest in, all of the Purchased Assets, free and clear
of all Liens,
and free of any material infractions or non-compliance with
applicable laws and
regulations (collectively, "Defects") and the sale and delivery of
the Purchased
Assets to Buyer pursuant hereto shall vest in Buyer good and
marketable title
thereto, free and clear of any and all Liens or Defects, other than
as disclosed
in SCHEDULE 3.6 hereto or as may be created by Buyer. The
Stockholder and each
Seller shall each, prior to the Closing, use their best efforts to
cure at their
expense any Defect identified by Buyer. Each Seller owns or leases
all property
and assets necessary for the conduct of their respective businesses
as such
businesses are presently conducted and are proposed to be
conducted, and all
such property and assets are included in the Purchased Assets. To
the knowledge
of the Stockholder and except as disclosed in SCHEDULE 3.6 hereto,
all tangible
properties and assets owned or leased by such Seller and contained
in the
Purchased Assets are in good operating
11
<Page>
condition and repair, ordinary wear and tear excepted, have been
well
maintained, and conform with all applicable laws, statutes,
ordinances, rules
and regulations.
3.7
INTELLECTUAL PROPERTY.
All patents, patent applications, proprietary
designs, copyrights, trade names, servicemarks, trademarks and
trademark
applications and proprietary know how which are currently owned by
or licensed
to each Seller are listed in SCHEDULE 3.7 attached hereto
("Intellectual
Property"). Except as set forth in SCHEDULE 3.7, the Intellectual
Property is
all of the intellectual property necessary for the operation of the
Business as
it is currently conducted. All of each Seller's patents, patent
applications and
trademarks have been registered in, filed in or issued by the
United States
Patent Office or the corresponding offices of other countries
identified in
SCHEDULE 3.7, and have been properly maintained and renewed in
accordance with
all applicable laws and regulations in the United States and each
such country.
To the knowledge of the Stockholder, all of the issued patents
within the
Intellectual Property are currently in compliance with applicable
formal legal
requirements (including payment of filing, examination or
maintenance fees) and
are valid and enforceable. Except as set forth in SCHEDULE 3.7 and
to the
knowledge of the Stockholder, the Intellectual Property's use does
not require
the consent of or payment to any other Person. To the knowledge of
the
Stockholder and except as set forth in SCHEDULE 3.7, the
Intellectual Property
is freely transferable and owned exclusively by each Seller, free
and clear of
any Liens. To the knowledge of the Stockholder and except as set
forth in
SCHEDULE 3.7, (a) no other Person has an interest in or right or
license to use,
or the right to license any other Person to use, any of the
Intellectual
Property, (b) there are no claims or demands of any other Person
pertaining
thereto and no proceedings have been instituted, or are pending or,
to the
knowledge of the Stockholder, threatened, which challenge any
Seller's rights in
respect thereof, (c) none of the Intellectual Property is being
infringed by
another Person or is subject to any outstanding order, decree,
ruling, charge,
injunction, judgment or stipulation, and (d) no Claim has been made
or, to the
knowledge of the Stockholder, is threatened charging such Seller
with
infringement of any adversely held Intellectual Property. With
respect to all
know-how that is included as part of the Intellectual Property, to
the knowledge
of the Stockholder, each Seller has taken all reasonable
precautions to protect
the secrecy, confidentiality and value of such know-how (including
the
enforcement by each Seller of a policy requiring each employee or
contractor to
execute proprietary information and confidentiality agreements
substantially in
the form of such Seller's standard form, a copy of which has been
provided to
Buyer).
3.8
CONTRACTS. Except for
contracts, commitments, leases, licenses, plans
and agreements described in SCHEDULE 3.8 attached hereto, no Seller
is a party
to or subject to:
(a) any plan or
contract regarding or providing for bonuses,
pensions, options, stock purchases, deferred compensation,
severance benefits
retirement payments, profit sharing, stock appreciation, collective
bargaining
or the like, or any contract or agreement with any labor union;
(b) any employment or
consulting contract or contract for personal
services not terminable at will by such Seller without penalty to
the Seller;
12
<Page>
(c) any contract or
agreement for the purchase of any commodity,
product, material, supplies, equipment or other personal property,
or for the
receipt of any service, other than purchase orders entered into in
the ordinary
course of business for less than $5,000 each and which in the
aggregate do not
exceed $25,000;
(d) any contract or
agreement for the purchase or lease of any fixed
asset, whether or not such purchase or lease is in the ordinary
course of
business, for a price in excess of $5,000;
(e) any contract or
agreement for the sale of any commodity, product,
material, equipment, or other personal property, or the furnishing
by such
Seller of any service, other than contracts with customers entered
into in the
ordinary course of business;
(f) any contract or
agreement providing for the purchase of all or
substantially all of its requirements of a particular product from
a supplier,
or for periodic minimum purchases of a particular product from a
supplier;
(g) any contract or
agreement concerning a partnership or joint
venture with one or more Persons;
(h) any
confidentiality agreement or any non-competition agreement or
other contract or agreement containing covenants limiting such
Seller's freedom
to compete in any line of business or in any location or with any
Person;
(i) any license
agreement (as licensor or licensee);
(j) any contract or
agreement with the Stockholder or any present or
former officer, director, consultant, agent or stockholder of such
Seller or
with any Affiliate of any of them;
(k) any loan
agreement, indenture, note, bond, debenture or any other
document or agreement evidencing a capitalized lease obligation or
Indebtedness
to any Person;
(l) any agreement of
guaranty, indemnification, or other similar
commitment with respect to the obligations or liabilities of any
other Person
(other than lawful indemnification provisions contained in the
Charters and
By-Laws of such Seller); or
(m) any other
agreement or contract (or group or related agreements
or contracts) under which the consequences of a default or
termination could
have a Material Adverse Effect or the performance of which
involves
consideration paid or received by the Seller in excess of
$5,000.
Copies of all such contracts, commitments, plans, leases, licenses
and
agreements have been provided to Buyer prior to the execution of
this Agreement,
and all such copies are true, correct and complete and have been
subject to no
amendment, extension or other modification as of the date hereof,
except such as
are described in SCHEDULE 3.8. Except as listed and described
13
<Page>
in SCHEDULE 3.8, none of the Sellers, or to the knowledge of the
Stockholder,
any other Person, is in default under any such contract,
commitment, plan,
lease, license or agreement and each such contact, commitment,
plan, lease,
license or agreement is in full force and effect and is valid and
enforceable in
accordance with its terms.
3.9
COMPLIANCE WITH LAWS.
Each Seller has conducted and is conducting its
business in compliance with applicable federal, state, local or
foreign laws,
statutes, ordinances, regulations, rules or orders or other
requirements of any
governmental, regulatory or administrative agency or authority or
court or other
tribunal relating to it. None of the Sellers are now charged with,
and to the
knowledge of the Stockholder, is not now under investigation with
respect to,
any possible violation of any applicable law, statute, ordinance,
regulation,
rule, order or requirement relating to any of the foregoing. Each
Seller has all
licenses, permits, franchises, orders, approvals, accreditations,
written
waivers and other authorizations as are necessary in order to
enable it to own
and conduct its business as currently conducted and as proposed to
be conducted
and to occupy and use its real and personal properties without
incurring any
material liability ("Necessary Permits"), except for such licenses,
permits,
franchises, orders, approvals, accreditations, written waivers and
other
authorizations as would not reasonably be expected to have a
Material Adverse
Effect. Except as set forth in SCHEDULE 3.9, no registration,
filing,
application, notice, transfer, consent, approval, order,
qualification, waiver
or other action of any kind is required by virtue of the execution
and delivery
of this Agreement or the consummation of the transactions
contemplated hereby to
effect the transfer to Buyer of such Necessary Permits. To the
knowledge of the
Stockholder, each Seller is in full compliance with the terms and
conditions of
all Necessary Permits.
3.10
LITIGATION. Except as disclosed on SCHEDULE 3.10 attached hereto,
(a)
there is no Claim pending or, to the knowledge of the Stockholder,
threatened
(or, to the knowledge of the Stockholder, any facts which could
lead to such a
Claim) by, against, affecting or regarding the Business or the
Sellers or the
Stockholder or their respective businesses, properties or assets,
at law or in
equity, before any federal, state, local or foreign court or any
other
governmental or administrative agency or tribunal or any arbitrator
or
arbitration panel, and (b) there are no judgments, orders, rulings,
charges,
decrees, injunctions, notices of violation or other mandates
against or
affecting the Business or the Sellers or the Stockholder with
respect to the
businesses, properties or assets of a Seller. Nothing listed on
SCHEDULE 3.10,
either individually or when aggregated with other listings on such
Schedule,
would reasonably be expected to have a Material Adverse Effect.
3.11
TAXES, EMPLOYEE BENEFITS AND ENVIRONMENTAL.
(a) The Stockholder is
not aware of any dispute or Claim concerning
any liability for Taxes of any Seller.
(b) No Seller has a
profit sharing, 401(k), disability, medical,
dental, severance pay, vacation pay, sick pay, deferred
compensation, incentive
compensation, fringe benefit, stay-with-bonus, change of control
agreement, or
other employee benefit plan, program, or agreement (other than
stock option
plans), including without limitation, any employee benefit plan as
defined in
section 3(3) of ERISA, which is maintained or contributed to by a
Seller, or
14
<Page>
under which such Seller has any liability or contingent
liability.
(c) The use and
operation by each Seller and by all past owners and
operators, of all facilities and properties used in the business of
each Seller
have been, and will be on the Closing Date, in compliance in all
material
respects with all Environmental Laws, and no Environmental Action
has been
filed, commenced, or, to the knowledge of the Sellers and the
Stockholder,
threatened with or against any of them alleging any failure so to
comply.
3.12
DISCLOSURE OF MATERIAL INFORMATION. This Agreement (including
the
Schedules and Exhibits hereto) does not contain, with respect to
each Seller or
the Stockholder, any untrue statement of a material fact or omits
to state a
material fact necessary to make the statements therein not
misleading in light
of the circumstances under which they were made. There is no fact
known to the
Stockholder which has or would reasonably be expected in the future
to result in
a Material Adverse Effect and which has not been set forth in this
Agreement or
previously disclosed in writing to the Buyer.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer hereby represents and warrants to each Seller and the
Stockholder as
follows:
4.1
ORGANIZATION AND
QUALIFICATION. Buyer is a corporation duly organized,
validly existing and in good standing under the laws of the State
of Delaware
with full power and authority to own, use or lease its properties
and to conduct
its business as such properties are owned, used or leased and as
such business
is conducted.
4.2
AUTHORITY. Buyer has
the requisite corporate power and authority to
enter into this Agreement and to carry out the transactions
contemplated hereby.
The execution, delivery and performance of this Agreement by Buyer
have been
duly and validly authorized and approved by all necessary corporate
action on
the part of Buyer, and this Agreement constitutes the legal and
binding
obligation of Buyer, enforceable against Buyer in accordance with
its terms.
Assuming the accuracy of the representations and warranties of the
Sellers and
the Stockholder hereunder and to the best knowledge of Buyer, the
entering into
of this Agreement by Buyer does not, and the consummation by Buyer
of the
transactions contemplated hereby will not, violate the provisions
of (a) any
applicable laws of the United States or any other state or
jurisdiction in which
Buyer does business, (b) the Charter or By-Laws of Buyer or (c) any
provision
of, or result in a default or acceleration of any obligation under,
or result in
any change in the rights or obligations of Buyer under, any
mortgage, Lien,
lease, agreement, contract, instrument, order, arbitration award,
judgment, or
decree to which Buyer is a party or by which Buyer is bound, or to
which any
property of Buyer is subject.
4.3
BROKERS. Neither Buyer
nor anyone acting on its behalf has engaged,
retained or incurred any liability to any broker, investment
banker, finder or
agent or has agreed to pay any brokerage fees, commissions,
finder's fees or
other fees with respect to the purchase of
15
<Page>
Purchased Assets, the issuance of the Consideration Shares, this
Agreement or
the transactions contemplated hereby.
4.4
BUYER FINANCIAL
STATEMENTS. Attached hereto as SCHEDULE 4.4 are the
following financial statements (collectively the "Buyer Financial
Statements"):
unaudited consolidated balance sheets and statements of income,
changes in
stockholders' equity and cash flow as of and for the fiscal year
ended December
31, 2002 of the Buyer. The Buyer Financial Statements have been
prepared in
accordance with GAAP applied on a consistent basis throughout the
periods
covered thereby, present fairly the financial condition of the
Buyer as of such
dates and the results of operations of the Buyer for such periods,
are correct
and complete, and are consistent with the books and records of the
Buyer, except
that the Buyer Financial Statements may not contain all footnotes
required by
GAAP and are subject to normal year-end audit adjustments.
4.5
FINANCIAL CONDITION.
Since the date of the Buyer Financial Statements,
there have been no subsequent events having a material adverse
effect on Buyer's
business, results of operations or financial condition. Buyer
represents that as
of the date of this Agreement, it currently has in excess of $50
million in a
combination of cash, cash equivalents and amounts committed under
investor
subscription agreements.
4.6
ONE CLASS OF STOCK.
Buyer has one class of capital stock outstanding,
and Buyer's certificate of incorporation, as amended or restated
through the
date hereof, authorizes no class of capital stock senior to the
Buyer's Common
Stock in terms of liquidation, dividend or redemption rights.
4.7
LITIGATION. Except as
disclosed on SCHEDULE 4.7 attached hereto, (a)
there is no Claim pending or, to the knowledge of the Buyer,
threatened (or, to
the knowledge of the Buyer, any facts which could lead to such a
Claim) by,
against, affecting or regarding the Buyer or its business,
properties or assets,
at law or in equity, before any federal, state, local or foreign
court or any
other governmental or administrative agency or tribunal or any
arbitrator or
arbitration panel that would reasonably be expected in the future
to have a
Material Adverse Effect, and (b) there are no judgments, orders,
rulings,
charges, decrees, injunctions, notices of violation or other
mandates against or
affecting the Buyer with respect to the business, properties or
assets of the
Buyer.
4.8
DISCLOSURE OF MATERIAL
INFORMATION. This Agreement (including the
Schedules and Exhibits hereto) does not contain, with respect to
the Buyer, any
untrue statement of a material fact or omits to state a material
fact necessary
to make the statements therein not misleading in light of the
circumstances
under which they were made.
16
<Page>
ARTICLE V
COVENANTS
5.1
COVENANTS OF THE
SELLERS AND THE STOCKHOLDER. Each Seller and the
Stockholder shall keep, perform and fully discharge the following
covenants and
agreements:
(a) INTERIM CONDUCT OF
BUSINESS. From the date hereof until the
Closing, each Seller shall operate its business consistent with
prior practice
immediately before the date hereof and in the ordinary course of
business
(except as may be authorized pursuant to this Agreement or as set
forth on
SCHEDULE 5.1(a) hereto). Without limiting the generality of the
foregoing, from
the date hereof until the Closing, except for transactions
contemplated by this
Agreement or expressly approved in writing by Buyer, no Seller
shall:
(i)
enter into or amend any employment, bonus, severance, or
retirement contract or arrangement, or increase any
compensation
payable or to become payable to any person other than in the
ordinary
course of business consistent with prior practice;
(ii)
purchase, lease or otherwise acquire any real estate or
any interest therein;
(iii) declare,
set aside or pay any dividend or make any other
distribution with respect to any Equity Security or authorize
for
issuance, issue, sell or deliver any of its own Equity Securities
or
split, combine or reclassify any class of Equity Security or redeem
or
otherwise acquire, directly or indirectly, any of its Equity
Securities;
(iv) merge
or consolidate with or agree to merge or
consolidate with, or purchase or agree to purchase all or
substantially all of the assets of, acquire securities of or
otherwise
acquire any Person;
(v)
sell, lease or otherwise dispose of or agree to sell,
lease or otherwise dispose of any of its assets, properties, rights
or
claims, whether tangible or intangible, except in the ordinary
course
of business consistent with prior practice;
(vi) incur
any liability, guaranty or obligation (fixed or
contingent) other than in the ordinary course of business
consistent
with prior practice or make any investment in excess of $5,000,
whether singly or in the aggregate, in property, plant and
equipment
and other items of capital expenditure;
(vii) place or
permit to be placed any Lien on any of its
assets or properties, other than statutory Liens arising in the
ordinary course of business;
17
<Page>
(viii) make or
authorize any amendments or changes to its
Charter or By-Laws; or
(ix)
abandon any part of its business not abandoned as of the
date hereof.
(b) ACCESS. Each
Seller shall, upon reasonable notice, give Buyer and
its representatives full and free access to all properties, assets,
books,
contracts, commitments and records of such Seller during reasonable
business
hours and shall promptly furnish Buyer with all financial and
operating data and
other information as to the history, ownership, Affiliates,
business, operations
and properties of such Seller as Buyer may from time to time
reasonably request.
(c) TRANSFER OF
NECESSARY PERMITS. From and after the date hereof
through to the Closing Date and following the Closing, each Seller
will use
reasonable commercial efforts to effect the transfer to Buyer of
all of the
Necessary Permits and all other permits, licenses (except the DFCI
License
Agreement), and leases which are associated with the Business as
presently
conducted, to the extent the same are by their terms
transferable.
(d) RETAINED
LIABILITIES. From and after the date hereof through to
the Closing Date and following the Closing, each Seller agrees to
pay, perform
and fully discharge all of the Retained Liabilities.
(e) SATISFACTION OF
CONDITIONS. Each Seller and the Stockholder shall
use their best efforts to accomplish the satisfaction of the
conditions
precedent to Closing contained in Section 6.1 herein on or prior to
the Closing
Date.
(f) NO SOLICITATION,
CONFIDENTIALITY, ETC. Prior to the termination
of this Agreement pursuant to Article VII hereof, no Seller or the
Stockholder
will (i) solicit or negotiate with respect to any inquiries or
proposals
relating to (x) the possible direct or indirect acquisition of any
Equity
Security of any Seller or of all or a portion of the Purchased
Assets or
Business or (y) any merger, consolidation, joint venture or
business combination
with any Seller or (ii) discuss or disclose either this Agreement
or other
confidential information pertaining to any Seller with any Person
(except as may
be required by law or except as may be r